ClinicalTrials.gg
CompletedNCT03690206EASE SBS 1Updated Jul 17, 2025Results posted

Efficacy And Safety Evaluation of Glepaglutide in Treatment of Short Bowel Syndrome (SBS)

A Phase 3 interventional study of glepaglutide and Placebo in Short Bowel Syndrome, sponsored by Zealand Pharma. Completed at 29 sites in 9 countries. Open to participants aged 18 Years to 90 Years. Per ClinicalTrials.gov, last updated 2025-07-17.

Sponsored by Zealand Pharma · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
106
Allocation
Randomized
Ages
18 Years to 90 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 80 studies in Short Bowel Syndrome with a site in United States — 11 open to participants now, 15 under way, 4 of them phase 3. Short Bowel Syndrome · United States.

Enrollment
7th of 66
106 · median 23
Started
2018
with 5 others
Phase 3
20 of 80
2 open now
Registered
54th of 80
by date
Lead sponsor
5 of 80
Zealand Pharma

Among the 80 studies in Short Bowel Syndrome with a site in United States, this one is the 7th largest by enrollment of the 66 interventional ones that give a count, is one of 6 that started in 2018, is one of 20 in phase 3, and was the 54th registered.

Short Bowel Syndrome

159 studies on the registry are indexed under Short Bowel Syndrome; 24 are open to participants now.

Browse Short Bowel Syndrome studies →

Open to participants now

11 of the 80 studies in Short Bowel Syndrome with a site in United States are open now. Recruiting first, the newest first:

6 more — sign in →

All 11 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 18 Short Bowel Syndrome studies recruiting now, 8 (44%) set no upper age limit and 8 (44%) stop at 75 or younger; 9 take children under 18; 2 take healthy volunteers.

This study: 18 Years to 90 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 80 studies in Short Bowel Syndrome with a site in United States, or all of them as a file.
02

Study summary

The primary objective of the trial is to confirm the efficacy of glepaglutide in reducing parenteral support volume in patients with short bowel syndrome.

Glepaglutide is the International Nonproprietary Name and USAN for ZP1848.

Read the detailed description

A Phase 3, international, multicenter, randomized, double-blind, placebo-controlled trial to evaluate the efficacy and safety of glepaglutide subcutaneous (SC) injections in patients with short bowel syndrome (SBS).

03

Conditions studied

  • Short Bowel Syndrome

Browse trials for

04

Who can participate

Ages eligible
18 Years to 90 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • obtained before any trial-related activity.
  • Diagnosis of SBS defined as remaining small bowel in continuity of estimated less than 200 cm and considered stable with regard to PS need. No restorative surgery planned in the trial period.
  • Requiring PS at least 3 days per week and maintains a stable PS volume for at least 2 weeks.
  • In case of remnant colon: documented colonoscopy which does not give rise to any safety concerns.

Exclusion criteria

Exclusion Criteria:

  • More than 2 SBS-related or PS-related hospitalizations within 6 months prior to Screening. No SBS-related hospitalizations within 30 days prior to randomization.
  • Poorly controlled inflammatory bowel disease that is moderately or severely active or fistula interfering with measurements or examinations required in the trial.
  • Bowel obstruction.
  • Known radiation enteritis or significant villous atrophy.
  • Cardiac disease defined as: decompensated heart failure ( [NYHA] Class III-IV), unstable angina pectoris, and/or myocardial infarction within the last 6 months prior to Screening.
  • abnormal .
  • Repeated systolic blood pressure measurements > 180 mm Hg.
  • positive, acute liver disease, or unstable chronic liver disease.
  • Any history of colon cancer. History of any other cancers unless disease-free state for at least 5 years.
  • Estimated \< 30 mL/min.
  • Severe hepatic impairment.
  • Use of GLP-1, GLP-2, human growth hormone, somatostatin, or analogs thereof, within 3 months prior to Screening.
  • Use of dipeptidyl peptidase (DPP)-4 inhibitors within 3 months prior to Screening.
  • Unstable systemic therapy within 3 months prior to Screening.
  • Unstable biological therapy within 6 months prior to Screening.
  • Females of , who are pregnant, breast-feeding, intend to become pregnant or are not using highly effective methods.
  • Previous exposure to glepaglutide.
  • Current, or within 30 days prior to Screening, participation in another interventional clinical trial that includes administration of an active compound.
  • Any condition or disease or circumstance that in the Investigator's opinion would put the patient at any undue risk, prevent completion of the trial, or interfere with the analysis of the trial results.
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
106 participants (actual)

Study arms

  • Experimental
    Glepaglutide SC injections twice weekly

    Intervention: Glepaglutide

    Drug: glepaglutide

  • Experimental
    Glepaglutide SC injections once weekly and placebo once weekly

    Intervention: Glepaglutide

    Drug: glepaglutide · Drug: Placebo

  • Placebo comparator
    Placebo SC injections twice weekly

    Intervention: Placebo

    Drug: Placebo

Interventions

  • Glucagon-Like Peptide-2 (GLP-2) analog

    Also known as: ZP1848

  • DrugPlacebo

    Placebo for glepaglutide

06

What researchers measure

Primary outcomes

  1. Change in Weekly Parenteral Support (PS) Volume

    Change in weekly PS volume from baseline to Week 24. Baseline actual weekly PS volume was defined as the actual PS volume derived from a valid 7-day period prior to visit 1 (Day 1), i.e. during the stabilization phase. The actual weekly PS volume at Weeks 1, 2, 4, 8, 12, 16, 20, and 24 was derived as the actual weekly PS volume received during the valid 7-day period prior to the visit. The source for the derivation was the PS volumes recorded by the patients in the eDiary.

    Time frame: 24 weeks

Secondary outcomes

  1. Clinical Response in PS Volume

    Clinical response, defined as at least 20% reduction in actual weekly PS volume from baseline to both Weeks 20 and 24.

    Time frame: 20 and 24 weeks

  2. Days Off PS

    Achieving 1 or more days per week off PS

    Time frame: 24 weeks

  3. Clinical Response in PS Volume

    Reduction of at least 20 percent in PS volume from baseline to both 12 and 24 weeks.

    Time frame: 12 and 24 weeks

  4. Weaned Off PS

    Reduction in weekly PS volume of 100 percent (weaned off)

    Time frame: 24 weeks

  5. Energy Content

    Change in weekly energy content of PS from baseline

    Time frame: 24 weeks

  6. Days on PS

    Change in number of days on PS per week from baseline

    Time frame: 24 weeks

  7. Change in PS Volume Per Week

    Achieving reduction of at least 40 percent in PS volume from baseline to both 20 and 24 weeks

    Time frame: 20 and 24 weeks

  8. Patient Global Impression of Change Scale (PGIC)

    Patient Global Impression of Change scale (PGIC) improvement at Weeks 4, 12, 20, and 24 PGIC improvement was defined as responding "Very Much Improved" or "Much Improved" on a 7-point Likert Scale. Improvement between each glepaglutide treatment regimen compared to placebo was tested by week, using the CMH test adjusted for the stratification factor. Improvement between each glepaglutide treatment regimen versus placebo was tested using collapsed categories of Improvement, No Change, and Worsening, where Improvement is defined as a response of "Very Much Improved" or "Much Improved" or "Minimally Improved", and No Change is defined as the response of "No Change", and Worsening is defined as a response of "Minimally Worse" or "Much Worse" or "Very Much Worse". Improvement using collapsed categories between each glepaglutide treatment regimen compared to placebo was tested by week using a Mantel-Haenszel chi-squared test for ordered categories.

    Time frame: 24 weeks

  9. Safety - Adverse Events

    Incidence and type of Adverse Events over an average of 28 weeks (24 weeks treatment + 4 weeks follow up)

    Time frame: 28 weeks

  10. Number of Patients With Clinically Significant Changes in 12-Lead Electrocardiogram (ECG)

    Number of patients with clinically significant changes in ECG will be reported. Monitored ECG parameters included heart rate (beats/min), PR interval (ms), PR interval Aggregate (ms), QRS duration aggregate (ms), QT interval aggregate (ms), QTcF interval aggregate (ms), and RR interval (ms), as well as the overall interpretation of each subject's ECG recorded as Normal, Abnormal Not Clinically Significant, or Abnormal Clinically Significant.

    Time frame: 28 weeks

  11. Safety - Changes in Blood Pressure From Baseline

    Changes in blood pressure are reported at Week 1, Week 2, Week 4, Week 8, Week 12, Week 16, Week 20, and Week 24 The data collected data are of seated diastolic and systolic blood pressure (mmHg). During treatment phase visits, vital signs were collected before investigational product injection.

    Time frame: Week 1, Week 2, Week 4, Week 8, Week 12, Week 16, Week 20, and Week 24

  12. Safety - Changes in Body Temperature From Baseline

    Changes in body temperature are reported The body temperature (ºC or ºF) was measured according to the site's usual procedure. During treatment phase visits, vital signs were collected before investigational product injection.

    Time frame: 28 weeks

  13. Immunogenicity - Occurrence of Anti-drug Antibodies

    Occurrence of antibodies against glepaglutide The occurrence of glepaglutide-binding antibodies (ADA), M2 binding antibodies (M2 BAb), glepaglutide neutralizing antibodies (NAb) and GLP-2 cross-reacting antibodies (GLP-2 CR) was tested.

    Time frame: 28 weeks

07

Results

Posted Oct 21, 2024

Participant flow

This trial was conducted in (number of sites that randomized patients in parenthesis) Belgium (1), Denmark (2), France (2), Germany (5), the Netherlands (1), Poland (3), Canada (3), the US (7), and the UK (5).

Participant flow — Overall Study
MilestoneGlepaglutide SC Injections Twice WeeklyGlepaglutide SC Injections Once Weekly and Placebo Once WeeklyPlacebo SC Injections Twice Weekly
Started353536
Completed313536
Not completed400
Withdrew: Withdrawal by subject200
Withdrew: Icf withdrawal200

Outcome measures

PrimaryChange in Weekly Parenteral Support (PS) Volume

Change in weekly PS volume from baseline to Week 24. Baseline actual weekly PS volume was defined as the actual PS volume derived from a valid 7-day period prior to visit 1 (Day 1), i.e. during the stabilization phase. The actual weekly PS volume at Weeks 1, 2, 4, 8, 12, 16, 20, and 24 was derived as the actual weekly PS volume received during the valid 7-day period prior to the visit. The source for the derivation was the PS volumes recorded by the patients in the eDiary.

Time frame:
24 weeks
Reported as:
Least squares mean · L/week
Change in Weekly Parenteral Support (PS) Volume
L/weekGlepaglutide SC Injections Twice WeeklyGlepaglutide SC Injections Once Weekly and Placebo Once WeeklyPlacebo SC Injections Twice Weekly
Change in Weekly Parenteral Support (PS) Volume-5.13 (-6.24 to -4.02)-3.76 (-4.96 to -2.56)-2.85 (-3.93 to -1.77)
Statistical analysis
  • Glepaglutide SC Injections Twice Weekly vs Placebo SC Injections Twice Weekly · Mixed Models Analysis · p = 0.0039 · Difference to placebo: -2.28 · 95% CI -3.83 to -0.73
  • Glepaglutide SC Injections Once Weekly and Placebo Once Weekly vs Placebo SC Injections Twice Weekly · Mixed Models Analysis · p = 0.2700 · Difference to placebo: -0.91 · 95% CI -2.52 to 0.71
SecondaryClinical Response in PS Volume

Clinical response, defined as at least 20% reduction in actual weekly PS volume from baseline to both Weeks 20 and 24.

Time frame:
20 and 24 weeks
Reported as:
Count of participants · Participants
Clinical Response in PS Volume
ParticipantsGlepaglutide SC Injections Twice WeeklyGlepaglutide SC Injections Once Weekly and Placebo Once WeeklyPlacebo SC Injections Twice Weekly
Clinical Response in PS Volume231614
Statistical analysis
  • Glepaglutide SC Injections Twice Weekly vs Placebo SC Injections Twice Weekly · Cochran-Mantel-Haenszel · p = 0.0243 · Difference to placebo: 26.6 · 95% CI 4.3 to 48.9
  • Glepaglutide SC Injections Once Weekly and Placebo Once Weekly vs Placebo SC Injections Twice Weekly · Cochran-Mantel-Haenszel · p = 0.6255 · Difference to placebo: 5.5 · 95% CI -16.2 to 27.1
SecondaryDays Off PS

Achieving 1 or more days per week off PS

Time frame:
24 weeks
Reported as:
Count of participants · Participants
Days Off PS
ParticipantsGlepaglutide SC Injections Twice WeeklyGlepaglutide SC Injections Once Weekly and Placebo Once WeeklyPlacebo SC Injections Twice Weekly
Days Off PS18127
Statistical analysis
  • Glepaglutide SC Injections Twice Weekly vs Placebo SC Injections Twice Weekly · Cochran-Mantel-Haenszel · p = 0.0043 · Difference to placebo: 31.7 · 95% CI 11.4 to 51.9
  • Glepaglutide SC Injections Once Weekly and Placebo Once Weekly vs Placebo SC Injections Twice Weekly · Cochran-Mantel-Haenszel · p = 0.1675 · Difference to placebo: 13.3 · 95% CI -5.4 to 32.0
SecondaryClinical Response in PS Volume

Reduction of at least 20 percent in PS volume from baseline to both 12 and 24 weeks.

Time frame:
12 and 24 weeks
Reported as:
Count of participants · Participants
Clinical Response in PS Volume
ParticipantsGlepaglutide SC Injections Twice WeeklyGlepaglutide SC Injections Once Weekly and Placebo Once WeeklyPlacebo SC Injections Twice Weekly
Clinical Response in PS Volume191513
SecondaryWeaned Off PS

Reduction in weekly PS volume of 100 percent (weaned off)

Time frame:
24 weeks
Reported as:
Count of participants · Participants
Weaned Off PS
ParticipantsGlepaglutide SC Injections Twice WeeklyGlepaglutide SC Injections Once Weekly and Placebo Once WeeklyPlacebo SC Injections Twice Weekly
Weaned Off PS540
Statistical analysis
  • Glepaglutide SC Injections Twice Weekly vs Placebo SC Injections Twice Weekly · Cochran-Mantel-Haenszel · p = 0.0160 · Difference to placebo: 14.1 · 95% CI 2.5 to 25.6
  • Glepaglutide SC Injections Once Weekly and Placebo Once Weekly vs Placebo SC Injections Twice Weekly · Cochran-Mantel-Haenszel · p = 0.0424 · Difference to placebo: 11.2 · 95% CI 0.7 to 21.6
SecondaryEnergy Content

Change in weekly energy content of PS from baseline

Time frame:
24 weeks
Reported as:
Median · kJ/week
Energy Content
kJ/weekGlepaglutide SC Injections Twice WeeklyGlepaglutide SC Injections Once Weekly and Placebo Once WeeklyPlacebo SC Injections Twice Weekly
Energy Content-7360.6 (-48521 to 130351)-3085.9 (-56550 to 1423)-734.2 (-46307 to 1670)
SecondaryDays on PS

Change in number of days on PS per week from baseline

Time frame:
24 weeks
Reported as:
Median · days/week
Days on PS
days/weekGlepaglutide SC Injections Twice WeeklyGlepaglutide SC Injections Once Weekly and Placebo Once WeeklyPlacebo SC Injections Twice Weekly
Days on PS-1.00 (-5.0 to 0.0)0.00 (-7.0 to 1.0)0.00 (-4.0 to 0.0)
SecondaryChange in PS Volume Per Week

Achieving reduction of at least 40 percent in PS volume from baseline to both 20 and 24 weeks

Time frame:
20 and 24 weeks
Reported as:
Count of participants · Participants
Change in PS Volume Per Week
ParticipantsGlepaglutide SC Injections Twice WeeklyGlepaglutide SC Injections Once Weekly and Placebo Once WeeklyPlacebo SC Injections Twice Weekly
Change in PS Volume Per Week15108
SecondaryPatient Global Impression of Change Scale (PGIC)

Patient Global Impression of Change scale (PGIC) improvement at Weeks 4, 12, 20, and 24 PGIC improvement was defined as responding "Very Much Improved" or "Much Improved" on a 7-point Likert Scale. Improvement between each glepaglutide treatment regimen compared to placebo was tested by week, using the CMH test adjusted for the stratification factor. Improvement between each glepaglutide treatment regimen versus placebo was tested using collapsed categories of Improvement, No Change, and Worsening, where Improvement is defined as a response of "Very Much Improved" or "Much Improved" or "Minimally Improved", and No Change is defined as the response of "No Change", and Worsening is defined as a response of "Minimally Worse" or "Much Worse" or "Very Much Worse". Improvement using collapsed categories between each glepaglutide treatment regimen compared to placebo was tested by week using a Mantel-Haenszel chi-squared test for ordered categories.

Time frame:
24 weeks
Reported as:
Number · participants
Patient Global Impression of Change Scale (PGIC)
participantsGlepaglutide SC Injections Twice WeeklyGlepaglutide SC Injections Once Weekly and Placebo Once WeeklyPlacebo SC Injections Twice Weekly
PGIC improved222713
PGIC much/very much improved17112
SecondarySafety - Adverse Events

Incidence and type of Adverse Events over an average of 28 weeks (24 weeks treatment + 4 weeks follow up)

Time frame:
28 weeks
Reported as:
Count of participants · Participants
Safety - Adverse Events
ParticipantsGlepaglutide SC Injections Twice WeeklyGlepaglutide SC Injections Once Weekly and Placebo Once WeeklyPlacebo SC Injections Twice Weekly
All AEs333327
Serious adverse events9107
AE Severity: Severe1052
AE Severity: Moderate151814
AE Severity: Mild283224
Relationship: Related272614
Relationship: Unlikely related18169
Relationship: Not related262623
AEs leading to trial withdrarwal200
AEs with action taken drug withdrawn210
AEs with action taken drug interrupted303
Outcome: Recovered/resolved323025
Outcome: Recovering/resolving795
Outcome: Recovered/resolved with sequelae110
Outcome: Not recovered/not resolved17149
Outcome: Fatal000
Outcome: Unknown100
Outcome: MIssing000
SecondaryNumber of Patients With Clinically Significant Changes in 12-Lead Electrocardiogram (ECG)

Number of patients with clinically significant changes in ECG will be reported. Monitored ECG parameters included heart rate (beats/min), PR interval (ms), PR interval Aggregate (ms), QRS duration aggregate (ms), QT interval aggregate (ms), QTcF interval aggregate (ms), and RR interval (ms), as well as the overall interpretation of each subject's ECG recorded as Normal, Abnormal Not Clinically Significant, or Abnormal Clinically Significant.

Time frame:
28 weeks
Reported as:
Count of participants · Participants
Number of Patients With Clinically Significant Changes in 12-Lead Electrocardiogram (ECG)
ParticipantsGlepaglutide SC Injections Twice WeeklyGlepaglutide SC Injections Once Weekly and Placebo Once WeeklyPlacebo SC Injections Twice Weekly
Number of Patients With Clinically Significant Changes in 12-Lead Electrocardiogram (ECG)000
SecondarySafety - Changes in Blood Pressure From Baseline

Changes in blood pressure are reported at Week 1, Week 2, Week 4, Week 8, Week 12, Week 16, Week 20, and Week 24 The data collected data are of seated diastolic and systolic blood pressure (mmHg). During treatment phase visits, vital signs were collected before investigational product injection.

Time frame:
Week 1, Week 2, Week 4, Week 8, Week 12, Week 16, Week 20, and Week 24
Reported as:
Least squares mean · mmHg
Safety - Changes in Blood Pressure From Baseline
mmHgGlepaglutide SC Injections Twice WeeklyGlepaglutide SC Injections Once Weekly and Placebo Once WeeklyPlacebo SC Injections Twice Weekly
Week 1 Systolic blood pressure-2.8 (-7.6 to 2.0)0.3 (-4.1 to 4.7)-4.5 (-8.2 to -0.7)
Week 2 Systolic blood pressure1.0 (-3.2 to 5.1)-0.1 (-4.6 to 4.4)-2.7 (-6.4 to 1.0)
Week 4 Systolic blood pressure-1.7 (-6.5 to 3.1)-0.2 (-3.9 to 3.4)-0.3 (-4.6 to 3.9)
Week 8 Systolic blood pressure0.3 (-5.4 to 6.0)-1.5 (-5.9 to 2.9)-2.5 (-6.9 to 1.8)
Week 12 Systolic blood pressure-4.4 (-9.6 to 0.8)3.3 (-1.0 to 7.6)-0.4 (-5.0 to 4.1)
Week 16 Systolic blood pressure0.1 (-5.6 to 5.8)0.4 (-4.7 to 5.5)-1.1 (-6.3 to 4.1)
Week 20 Systolic blood pressure1.3 (-5.8 to 8.3)1.2 (-3.6 to 6.0)-1.0 (-6.2 to 4.3)
Week 24 Systolic blood pressure-1.0 (-6.2 to 4.1)-1.1 (-5.6 to 3.4)-5.9 (-11.0 to -0.8)
Week 1 Diastolic blood pressure0.4 (-2.3 to 3.0)0.5 (-2.6 to 3.5)-2.0 (-4.6 to 0.6)
Week 2 Diastolic blood pressure2.5 (0.2 to 4.7)-0.7 (-3.1 to 1.7)-1.7 (-5.0 to 1.6)
Week 4 Diastolic blood pressure0.0 (-2.8 to 2.8)-0.2 (-2.5 to 2.8)-1.5 (-4.6 to 1.6)
Week 8 Diastolic blood pressure-0.5 (-3.3 to 2.3)1.9 (-1.3 to 5.0)-0.6 (-3.3 to 2.2)
Week 12 Diastolic blood pressure-2.8 (-6.7 to 1.2)2.0 (-1.0 to 5.1)0.9 (-1.8 to 3.6)
Week 20 Diastolic blood pressure2.1 (-1.5 to 5.7)-0.7 (-3.9 to 2.4)0.4 (-3.3 to 4.1)
Week 24 Diastolic blood pressure2.2 (-1.6 to 5.9)0.0 (-2.7 to 2.7)-0.9 (-3.8 to 2.1)
SecondarySafety - Changes in Body Temperature From Baseline

Changes in body temperature are reported The body temperature (ºC or ºF) was measured according to the site's usual procedure. During treatment phase visits, vital signs were collected before investigational product injection.

Time frame:
28 weeks
Reported as:
Least squares mean · degree C
Safety - Changes in Body Temperature From Baseline
degree CGlepaglutide SC Injections Twice WeeklyGlepaglutide SC Injections Once Weekly and Placebo Once WeeklyPlacebo SC Injections Twice Weekly
Week 10.0 (-0.1 to 0.2)-0.0 (-0.2 to 0.1)0.1 (-0.0 to 0.2)
Week 20.1 (-0.0 to 0.2)-0.0 (-0.2 to 0.1)0.0 (-0.1 to 0.1)
Week 4-0.1 (-0.2 to 0.1)-0.0 (-0.2 to 0.1)0.1 (-0.1 to 0.2)
Week 80.0 (-0.1 to 0.2)0.1 (-0.0 to 0.2)-0.1 (-0.2 to 0.1)
Week 12-0.0 (-0.2 to 0.1)-0.0 (-0.1 to 0.1)0.1 (-0.1 to 0.2)
Week 16-0.0 (-0.1 to 0.1)-0.0 (-0.1 to 0.1)0.0 (-0.1 to 0.1)
Week 200.1 (-0.1 to 0.2)0.0 (-0.1 to 0.1)0.1 (-0.1 to 0.2)
Week 24-0.0 (-0.1 to 0.1)0.1 (-0.0 to 0.2)0.1 (0.0 to 0.2)
SecondaryImmunogenicity - Occurrence of Anti-drug Antibodies

Occurrence of antibodies against glepaglutide The occurrence of glepaglutide-binding antibodies (ADA), M2 binding antibodies (M2 BAb), glepaglutide neutralizing antibodies (NAb) and GLP-2 cross-reacting antibodies (GLP-2 CR) was tested.

Time frame:
28 weeks
Reported as:
Count of participants · Participants
Immunogenicity - Occurrence of Anti-drug Antibodies
ParticipantsGlepaglutide SC Injections Twice WeeklyGlepaglutide SC Injections Once Weekly and Placebo Once WeeklyPlacebo SC Injections Twice Weekly
ADA (Treatment-induced)30310
M2 BAb (Treatment-induced)28290
NAb M2 (Treatment-induced)10140
GLP-2 CR (Treatment-induced)6110

Adverse events

Collected over All AEs, whether serious or non-serious, were to be reported from the time a signed and dated Informed Consent Form (ICF) was obtained until the end of the post-treatment follow-up period on average 28 weeks.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Glepaglutide SC Injections Twice Weekly0/35 (0%)9/35 (25.7%)30/35 (85.7%)
Glepaglutide SC Injections Once Weekly and Placebo Once Weekly0/35 (0%)10/35 (28.6%)31/35 (88.6%)
Placebo SC Injections Twice Weekly0/36 (0%)7/36 (19.4%)25/36 (69.4%)
Most frequent serious events
Showing 10 of 24
Most frequent serious events
EventGlepaglutide SC Injections Twice WeeklyGlepaglutide SC Injections Once Weekly and Placebo Once WeeklyPlacebo SC Injections Twice Weekly
Stoma site haemorrhageInjury, poisoning and procedural complications1/170/200/21
PyrexiaGeneral disorders1/352/350/36
Device related sepsisInfections and infestations2/352/351/36
Vascular device infectionInfections and infestations0/352/352/36
Acetabulum fractureInjury, poisoning and procedural complications1/350/350/36
Peripheral arterial occlusive diseaseVascular disorders0/351/350/36
DizzinessNervous system disorders1/350/350/36
Blood loss anaemiaBlood and lymphatic system disorders1/350/350/36
Iron deficiency anaemiaBlood and lymphatic system disorders1/350/350/36
Catheter site necrosisGeneral disorders0/351/350/36
Most frequent other events
Showing 10 of 49
Most frequent other events
EventGlepaglutide SC Injections Twice WeeklyGlepaglutide SC Injections Once Weekly and Placebo Once WeeklyPlacebo SC Injections Twice Weekly
Injection site reactionGeneral disorders9/3515/351/36
Stoma site oedemaInjury, poisoning and procedural complications4/172/200/21
NauseaGastrointestinal disorders7/353/351/36
Injection site erythemaGeneral disorders5/356/351/36
Abdominal painGastrointestinal disorders5/356/352/36
VomitingGastrointestinal disorders3/356/350/36
HeadacheNervous system disorders4/353/353/36
PyrexiaGeneral disorders4/351/351/36
FatigueGeneral disorders4/354/350/36
Injection site painGeneral disorders4/353/350/36

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)Glepaglutide SC Injections Twice WeeklyGlepaglutide SC Injections Once Weekly and Placebo Once WeeklyPlacebo SC Injections Twice WeeklyTotal
<=18 years0000
Between 18 and 65 years23283081
>=65 years127625
Age, Continuous
Age, Continuous(years)Glepaglutide SC Injections Twice WeeklyGlepaglutide SC Injections Once Weekly and Placebo Once WeeklyPlacebo SC Injections Twice WeeklyTotal
Mean56.9 ± 13.454.0 ± 12.055.0 ± 11.855.0 ± 12.4
Sex: Female, Male
Sex: Female, Male(Participants)Glepaglutide SC Injections Twice WeeklyGlepaglutide SC Injections Once Weekly and Placebo Once WeeklyPlacebo SC Injections Twice WeeklyTotal
Female19182057
Male16171649
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Glepaglutide SC Injections Twice WeeklyGlepaglutide SC Injections Once Weekly and Placebo Once WeeklyPlacebo SC Injections Twice WeeklyTotal
Hispanic or Latino0101
Not Hispanic or Latino30333295
Unknown or Not Reported51410
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Glepaglutide SC Injections Twice WeeklyGlepaglutide SC Injections Once Weekly and Placebo Once WeeklyPlacebo SC Injections Twice WeeklyTotal
American Indian or Alaska Native0000
Asian1001
Native Hawaiian or Other Pacific Islander0000
Black or African American1113
White28313089
More than one race0000
Unknown or Not Reported53513
Region of Enrollment
Region of Enrollment(participants)Glepaglutide SC Injections Twice WeeklyGlepaglutide SC Injections Once Weekly and Placebo Once WeeklyPlacebo SC Injections Twice WeeklyTotal
Canada1034
Netherlands2024
Belgium34310
United States413623
Denmark5218
Poland871227
United Kingdom4419
France5139
Germany34512
BMI
BMI(kg/m^2)Glepaglutide SC Injections Twice WeeklyGlepaglutide SC Injections Once Weekly and Placebo Once WeeklyPlacebo SC Injections Twice WeeklyTotal
Mean23.57 ± 3.3522.72 ± 3.2123.54 ± 3.5723.28 ± 3.37
08

Study locations

29 sites
  • Georgetown University Medical Center
    Washington D.C., District of Columbia 20007, United States
  • University of Chicago Children's Hospital
    Chicago, Illinois 60637, United States
  • Mayo Clinic College of Medicine
    Rochester, Minnesota 55905, United States
  • University of Nebraska Medical Center
    Omaha, Nebraska 68198-3285, United States
  • Mount Sinai Hospital
    New York, New York 10029, United States
  • Cleveland Clinic
    Cleveland, Ohio 44195, United States
  • Vanderbilt University Medical Center, Nashville
    Nashville, Tennessee 68198-3285, United States
  • UZ Leuven
    Leuven, Belgium
  • The Royal Alexandra Hospital
    Edmonton, Canada
  • Western University
    London, N6A 4V2, Canada
  • University Health Network - Toronto General Hospital
    Toronto, Canada
  • Aalborg University Hospital
    Aalborg, 9000, Denmark
  • Rigshospitalet
    Copenhagen, Denmark
  • Hôpital Beaujon
    Clichy, France
  • Centre Hospitalier Lyon-Sud
    Pierre-Bénite, France
  • Charité - Universitätsmedizin Berlin
    Berlin, Germany
  • Universitätsklinikum Bonn
    Bonn, Germany
  • Universitätsklinikum Frankfurt - Med. Klinik I
    Frankfurt, Germany
  • Asklepios Kliniken Hamburg GmbH
    Hamburg, Germany
  • Universitätsmedizin Rostock
    Rostock, Germany
  • UMC Radboud Nijmegen
    Nijmegen, Netherlands
  • Wojewodzki Specjalistyczny Szpital im. M. Pirogowa w Lodzi
    Lodz, Poland
  • Solumed
    Poznan, Poland
  • Szpital Skawina sp. z o.o. im. Stanley Dudricka
    Skawina, Poland
  • St Mark's Hospital
    Harrow, United Kingdom
  • UCLH Foundation NHS Trust
    London, United Kingdom
  • Salford Royal NHS Foundation Trust
    Manchester, United Kingdom
  • University of East Anglia
    Norwich, United Kingdom
  • University Hospital Southampton NHS Foundation Trust
    Southampton, United Kingdom
09

References and documents

Publications

  • Jeppesen PB, Vanuytsel T, Subramanian S, Joly F, Wanten G, Lamprecht G, Kunecki M, Rahman F, Nielsen TSS, Berner-Hansen M, Pape UF, Mercer DF. Glepaglutide, a Long-Acting Glucagon-like Peptide-2 Analogue, Reduces Parenteral Support in Patients With Short Bowel Syndrome: A Phase 3 Randomized Controlled Trial. Gastroenterology. 2025 Apr;168(4):701-713.e6. doi: 10.1053/j.gastro.2024.11.023. Epub 2024 Dec 19. PubMed 39708985 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Oct 2018 to primary completion in Jul 2022, 45 months.

Results were first posted in Oct 2024, 2 years 2 months after primary completion. A results delay was requested in May 2023.

Of 26 industry-sponsored phase 3 interventional studies under Short Bowel Syndrome, half reached primary completion within 36 months of starting (the median), counting those still running; a quarter within 20 and three quarters within 45. This study's 45 months is above that.

Counting every sponsor, half of 27 studies reached it within 37 months; a quarter within 24 and three quarters within 46.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 17, 2018
First posted
Oct 1, 2018
StartActual
Oct 4, 2018
Primary completionActual
Jul 26, 2022
CompletionActual
Jul 26, 2022
Results delay requested
May 23, 2023
Results first posted
Oct 21, 2024
Last update
Jul 17, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 17, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03690206
Lead sponsor
Zealand Pharma
Responsible party
Sponsor
First posted
Oct 1, 2018
Start date
Oct 4, 2018
Primary completion
Jul 26, 2022
Completion
Jul 26, 2022
Results posted
Oct 21, 2024
Last update
Jul 17, 2025

Study contacts

Study Director
study director · Zealand Pharma

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Glepaglutide

Start the discussion